Jan282020UncategorizedCategory: UncategorizedBy Charlotte Maddalena28 January 2020 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA Pharma announces the commercial launch of Kigabeq® in FranceNextNext post:First patient treated with anti-CD39 mAb IPH5201 on OREGA’s 10-year anniversary dayRelated PostsORPHELIA Pharma collaborates with Oscar Lambret clinical center11 June 2024ORPHELIA Pharma recrute un/une Chef de Projet Réglementaire Senior7 June 2024ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024Six new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024
ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024
Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024
